Arsthinol
Arsthinol (INN) is an antiprotozoal agent. It was synthesized for the first time in 1949 by Ernst A.H. Friedheim by complexation of acetarsol with 2,3-dimercaptopropanol (British anti-Lewisite) and has been demonstrated to be effective against amoebiasis and yaws. It was marketed few years later by Endo Products (Balarsen, Tablets, 0.1 g). Among trivalent organoarsenicals, arsthinol was considered as very well tolerated. Recently, it was studied for its anticancer activity.
Names | |
---|---|
Preferred IUPAC name
N-{2-Hydroxy-5-[4-(hydroxymethyl)-1,3,2-dithiarsolan-2-yl]phenyl}acetamide | |
Identifiers | |
3D model (JSmol) |
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.003.965 |
EC Number |
|
KEGG | |
PubChem CID |
|
UNII | |
| |
SMILES
| |
Properties | |
C11H14AsNO3S2 | |
Molar mass | 347.28 g·mol−1 |
Pharmacology | |
P01AR01 (WHO) QP51AD01 (WHO) | |
Routes of administration |
Oral |
Pharmacokinetics: | |
Metabolism |
89 % Hepatic |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.